ID: 4342754 A MULTICENTER, PLACEBO-CONTROLLED, PHASE 3 STUDY OF ETRIPAMIL IN PATIENTS WITH ATRIAL FIBRILLATION AND RAPID VENTRICULAR RATE: REVERA-301 TRIAL DESIGN
Atrial fibrillation (AF) can be associated with rapid ventricular rates (RVR) that require rate control to alleviate symptoms. Oral medications can have a delayed and ineffective response, prompting patients to seek emergency care for intravenous drug or cardioversion. Etripamil nasal spray is a fast-acting, non-dihydropyridine calcium channel blocker in development to treat paroxysmal supraventricular tachycardia and AF-RVR. Phase 2 data suggest etripamil can reduce the rate of AF-RVR and improve patient satisfaction.
Authors
- Peter R. Kowey (ORCID: https://orcid.org/0000-0001-7189-1638)
- Sean D. Pokorney (ORCID: https://orcid.org/0000-0002-4345-0816)
- A. John Camm (ORCID: https://orcid.org/0000-0002-2536-2871)
- Martin E W Hemels (ORCID: https://orcid.org/0000-0002-2373-9858)
- Benjamin Adam Steinberg (ORCID: https://orcid.org/0000-0002-4729-7820)
- Jonathan Paul Piccini (ORCID: https://orcid.org/0000-0003-0772-2404)
- James E. Ip (ORCID: https://orcid.org/0000-0002-3461-505X)
- Paul Dorian (ORCID: https://orcid.org/0000-0002-8244-3520)
- Denis Roy (ORCID: https://orcid.org/0000-0002-4540-2607)
- Marco Alings
- David B. Bharucha
Publication Details
- Journal
- Heart Rhythm O2
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1016/j.hroo.2025.07.084
- Primary Topic
- Cardiac electrophysiology and arrhythmias
- Type
- article
- Field-Weighted Citation Impact
- 0.00